1.Does targeted therapy have a preventive effect on patients after radical kidney cancer surgery? Targeted therapy is currently only approved for patients with metastatic kidney cancer. For patients who have undergone radical kidney cancer surgery, there is no clear evidence that it can prevent tumor recurrence after surgery, and relevant clinical trials are underway. 2.Does targeted therapy have therapeutic effect on patients with advanced stage who cannot have surgery? What are the side effects of this treatment? Numerous studies have shown that the application of targeted drugs can effectively shrink the tumor and metastases and prolong the survival rate of patients with kidney cancer that cannot be removed surgically. Sotan and doxorubicin are two of the most effective targeted drugs for kidney cancer. Patients who use these drugs at full dose often experience treatment side effects such as sclerodactyly, hypertension, leukopenia and thrombocytopenia, abnormal liver function, fatigue, weakness, anorexia, nausea, vomiting, diarrhea, abdominal pain, constipation, and change in taste. Patients should contact their treating physician to reduce or discontinue the medication as soon as these symptoms occur.